Clinical Trial Detail

NCT ID NCT04471415
Title First-in-human Study of DRP-104 as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors.
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Dracen Pharmaceuticals, Inc.
Indications

lung non-small cell carcinoma

hypopharynx cancer

head and neck squamous cell carcinoma

oral cavity cancer

Advanced Solid Tumor

laryngeal squamous cell carcinoma

oropharynx cancer

Therapies

DRP-104

Atezolizumab + DRP-104

Age Groups: adult senior

Additional content available in CKB BOOST